drugset / Trial / NCT03172988

Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery

NCT03172988

RandomizedFactorialQuadruple-blindSupportive care

Summary

Surgical resection is the first choice treatment for patients with non-small-cell lung cancer. Despite of advances in surgical techniques, the long-term survival rate of postoperative patient is far from optimal. In a recent retrospective cohort study of the applicants, 588 patients after surgery for non-small-cell lung cancer were followed up for a medium of 5.2 years. The results showed that perioperative use of dexamethasone was associated with prolonged survival; perioperative use of flurbiprofen axetil was also associated with a slightly longer survival but not statistically significant. Further analysis showed that combined administration of dexamethasone and flurbiprofen axetil had additive effect in prolonging survival. We hypothesize that, for patients undergoing surgery for non-small-cell lung cancer, perioperative administration of dexamethasone and flurbiprofen axetil may improve long-term survival. However, evidences from randomized controlled trials are still lacking in this aspect.

Timeline

Start
2017-08-02
Primary completion
2018-12-26
Completion
2018-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 10 mg
Subject flurbiprofen axetil Other / unclassified 2 mg/ml
Subject flurbiprofen axetil Other / unclassified 50 mg